Business Description
Passage Bio is a Philadelphia-based biotechnology company founded in 2017 that focuses on developing gene-based treatments for serious neurological conditions. Its pipeline targets several rare and debilitating diseases, including frontotemporal dementia, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy, ALS, and Huntington's disease. The company works closely with the University of Pennsylvania's Gene Therapy Program and has a manufacturing partnership with Catalent Maryland to support the development and supply of its treatments.
